JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v4i3.2341 jpsim.v4i3.2341 Original Research Assessment of Efficacy and Safety of Ivermectin in the Patients of COVID-19 Mahmood Atif Khan Asma afzal.a3s3@gmail.com * Shahbaz Ayesha Pervaiz Saira Department of Pulmonology Fatima Memorial Hospital,Lahore *Correspondence: Asma Khan (afzal.a3s3@gmail.com) 25 09 2023 2023 4 3 206 209 17 05 2023 08 07 2023 Copyright © 2023 The Author(s) 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

Primary objective of the study is to evaluate the efficacy and safety of ivermectin in reducing the progression and severity of Covid-19. Secondary objective of the study is to compare viral clearance rate among the study group and evaluation of side effects of therapy.

 Methodology

This cross-sectional observational study was undertaken at Department of Pulmonology Fatima Memorial Hospital, Lahore. After taking a medical history and doing a physical examination, oral ivermectin(12 mg once daily for 5 days) was given to 350 patients with COVID-19. Throughout treatment, the clinical efficacy of ivermectin, viral clearance rate, and adverse effects of medication were assessed and recorded on a prepared Performa.

 Results

Ivermectin therapy demonstrated 99.9 percent efficacy in patients treated with it. The paired sample t test revealed statistically significant differences in radiographic findings and PCR laboratory examination prior to and following ivermectin administration. While all clinical symptoms improved following medication. On the other hand, 2 persons (4%) have reported experiencing adverse effects from the medicine.

 Conclusion

Ivermectin induction has been presented as a more successful technique for treating Covid-19 infection.

 Keywords Ivermectin Covid-19 anti-helmenthic References Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103(2):214-6. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 2020;178(1):1-4. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam R, Robin R. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. J Bangladesh Coll Physic Surg. 2020;38(1):10–5 Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study. Chest. 2021;159(1):85-92. Arévalo AP, Pagotto R, Pórfido JL, Daghero H, Segovia M, Yamasaki K, et al. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Scient Repo. 2021;11(1):7132. Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo. 2020;34(5):3023-3026. Tay MY, Fraser JE, Chan WK. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin. Antiviral Res. 2013;99(3):301-306. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851-856. Barrows NJ, Campos RK, Powell ST. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe. 2016;20(2):259-270. Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008;57(11):524-529. DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart. 2020;7(2). Ci X, Li H, Yu Q. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol. 2009;23(4):449-55. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178(6):104787. Masoud HH, Elassal G, Hassany M, Zaky S. Management Protocol for COVID-19 Patients. Ministry of health and population (MOHP), Egypt. Version 1.4; 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021; 103(2): 214- 6. Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Res Square. 2020; doi: 10.21203/rs.3.rs-100956/v3. Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Clin Microbiol Antimicrob. 2020; 19(1): 23. Jans DA, Martin AJ, Wagstaff KM. Inhibitors of nuclear transport. Curr Opin Cell Biol. 2019; 58(2): 50- 60. Gorial FI, Mashhadani S, Sayaly HM. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). 2020; doi:10.1101/2020.07.07.20145979 Khan SI, Khan SI, Debnath CR. Ivermectin treatment may improve the prognosis of patients with COVID-19. Arch Bronconeumol. 2020; 56(12): 828-30. Podder CS, Chowdhury N, Mohim IS, Haque W. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study. IMC J Med Sci. 2020; 14(3):002. Chachar AZK, Khan KA, Asif M, Tanveer K, Khaqan A, Basri R. Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. Int J Sci. 2020;9(9): 31-5.